Erratum (DOI:10.1016/j.bbmt.2006.12.454);Cytomegalovirus Infections following Umbilical Cord Blood Transplantation Using Reduced Intensity Conditioning Regimens for Adult Patients

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 5, 2007, Pages 577-583

  Matsumura, Tomoko ^a,b   Narimatsu, Hiroto ^a   Kami, Masahiro ^b   Yuji, Koichiro ^a   Kusumi, Eiji ^a   Hori, Akiko ^b   Murashige, Naoko ^c   Tanaka, Yuji ^b   Masuoka, Kazuhiro ^a   Wake, Atsushi ^a   Miyakoshi, Shigesaburo ^a   Kanda, Yoshinobu ^d   Taniguchi, Shuichi ^a  

^a TORANOMON HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

CD34 positive cells; Cytomegalovirus antigenemia; Foscarnet; Ganciclovir; Graft versus host disease

Indexed keywords

BUSULFAN; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIGEN PP65; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADRENAL DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CELL COUNT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTINUOUS INFUSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATIENT MONITORING; REDUCED INTENSITY CONDITIONING; RETINITIS; SIDE EFFECT; T CELL LEUKEMIA; UMBILICAL CORD BLOOD; VIREMIA; VIRUS INACTIVATION; VIRUS PNEUMONIA; VIRUS REACTIVATION; WHOLE BODY RADIATION;

EID: 34247102213     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.02.011     Document Type: Erratum

References (51)

1. Gluckman E. Hematopoietic stem-cell transplants using umbilical-cord blood. N Engl J Med. 344 (2001) 1860-1861
2. Rubinstein P., Carrier C., Scaradavou A., et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 339 (1998) 1565-1577
3. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 351 (2004) 2276-2285
4. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 351 (2004) 2265-2275
5. Barker J.N., Weisdorf D.J., DeFor T.E., Blazar B.R., Miller J.S., and Wagner J.E. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102 (2003) 1915-1919
6. Miyakoshi S., Yuji K., Kami M., et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res. 10 (2004) 3586-3592
7. Saavedra S., Sanz G.F., Jarque I., et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant. 30 (2002) 937-943
8. Tomonari A., Iseki T., Ooi J., et al. Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan. Br J Haematol. 121 (2003) 304-311
9. Remberger M., Ringden O., Blau I.W., et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 98 (2001) 1739-1745
10. Bacigalupo A., Zikos P., Van Lint M.T., et al. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience. Exp Hematol. 26 (1998) 409-414
11. Nishihira H., Kato K., Isoyama K., et al. The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis. Br J Haematol. 120 (2003) 516-522
12. Kanda Y., Mineishi S., Saito T., et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 28 (2001) 689-692
13. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 34 (2002) 730-751
14. Narimatsu H., Kami M., Hara S., et al. Intestinal thrombotic microangiopathy following reduced-intensity umbilical cord blood transplantation. Bone Marrow Transplant 36 (2005) 517-523
15. Sullivan K.M., Agura E., Anasetti C., et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 28 (1991) 250-259
16. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825-828
17. Kanda Y., Mineishi S., Saito T., et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 27 (2001) 437-444
18. Sommadossi J.P., Bevan R., Ling T., et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis. 10 Suppl 3 (1988) S507-S514
19. Gooley T.A., Leisenring W., Crowley J., and Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 18 (1999) 695-706
20. Kishi Y., Kami M., Miyakoshi S., et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation 80 (2005) 34-40
21. Junghanss C., Boeckh M., Carter R.A., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99 (2002) 1978-1985
22. Kanda Y., Mineishi S., Saito T., et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. Transplantation 73 (2002) 568-572
23. Kusumi E., Kami M., Yuji K., et al. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transplant. 33 (2004) 697-702
24. Nichols W.G., Corey L., Gooley T., Davis C., and Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 185 (2002) 273-282
25. Yanada M., Yamamoto K., Emi N., et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 32 (2003) 801-807
26. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., and Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355 (2000) 2032-2036
27. Montagna D., Locatelli F., Moretta A., et al. T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. Blood 103 (2004) 4322-4329
28. Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., and Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102 (2003) 4255-4260
29. Moretta A., Maccario R., Fagioli F., et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol. 29 (2001) 371-379
30. Thomson B.G., Robertson K.A., Gowan D., et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 96 (2000) 2703-2711
31. Gluckman E., Rocha V., Boyer-Chammard A., et al., Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 337 (1997) 373-381
32. Locatelli F., Rocha V., Chastang C., et al., Eurocord-Cord Blood Transplant Group. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Blood 93 (1999) 3662-3671
33. Rocha V., Cornish J., Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97 (2001) 2962-2971
34. Narimatsu H., Matsumura T., Kami M., et al. Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients. Biol Blood Marrow Transplant. 11 (2005) 429-436
35. Marr K.A., Carter R.A., Boeckh M., Martin P., and Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002) 4358-4366
36. Nakamura R., Battiwalla M., Solomon S., et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant. 10 (2004) 49-57
37. Narimatsu H., Terakura S., Matsuo K., et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transplant. 39 (2007) 31-39
38. Ohnishi M., Sakurai T., Heike Y., et al. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br J Haematol. 131 (2005) 472-479
39. Machida U., Kami M., Fukui T., et al. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J Clin Microbiol. 38 (2000) 2536-2542
40. Moretti S., Zikos P., Van Lint M.T., et al. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant. 22 (1998) 175-180
41. Reusser P., Einsele H., Lee J., et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99 (2002) 1159-1164
42. Castro-Malaspina H., Harris R.E., Gajewski J., et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99 (2002) 1943-1951
43. Ljungman P., Aschan J., Lewensohn-Fuchs I., et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 66 (1998) 1330-1334
44. Enright H., Haake R., Weisdorf D., et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 55 (1993) 1339-1346
45. Samuels B.L., and Bitran J.D. High-dose intravenous melphalan: a review. J Clin Oncol. 13 (1995) 1786-1799
46. Mori T., Mori S., Kanda Y., et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 33 (2004) 431-434
47. van Burik J.A., Lawatsch E.J., DeFor T.E., and Weisdorf D.J. Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 7 (2001) 674-679
48. Kakugawa Y., Kami M., Kozu T., et al. Endoscopic evaluation for cytomegalovirus enterocolitis after allogeneic hematopoietic stem cell transplantation. Gut 55 (2006) 895-896
49. Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol. 28 (2000) 1197-1205
50. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., and Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88 (1996) 4063-4071
51. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101 (2003) 407-414